These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2127690)

  • 41. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
    Seltzer V; Vogl S; Kaplan B
    Gynecol Oncol; 1985 Jun; 21(2):167-76. PubMed ID: 3921437
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
    Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
    J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
    Brower MS; Coleman M; Pasmantier MW; Silver RT; Mamaril AP; Quiguyan CC
    Med Pediatr Oncol; 1984; 12(1):17-24. PubMed ID: 6321930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
    Wiernik PH; Yeap B; Vogl SE; Kaplan BH; Comis RL; Falkson G; Davis TE; Fazzini E; Cheuvart B; Horton J
    Cancer Invest; 1992; 10(1):1-9. PubMed ID: 1735009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
    Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
    Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
    [No Abstract]   [Full Text] [Related]  

  • 46. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
    Belinson JL; Pretorius RG; McClure M; Ashikaga T
    Gynecol Oncol; 1986 Mar; 23(3):304-9. PubMed ID: 3082726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
    Bruckner HW; Cohen CJ; Feuer E; Wallach RC; Kabakow B; Holland JF
    Obstet Gynecol; 1987 Jan; 69(1):114-20. PubMed ID: 3099235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altretamine.
    Hansen LA; Hughes TE
    DICP; 1991 Feb; 25(2):146-52. PubMed ID: 1905441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
    [No Abstract]   [Full Text] [Related]  

  • 51. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.
    Fetting JH; Gray R; Fairclough DL; Smith TJ; Margolin KA; Citron ML; Grove-Conrad M; Cella D; Pandya K; Robert N; Henderson IC; Osborne CK; Abeloff MD
    J Clin Oncol; 1998 Jul; 16(7):2382-91. PubMed ID: 9667255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
    Laufman LR; Green JB; Alberts DS; O'Toole R; Hilgers RD; Young DC; Lin F; Rivkin SE
    J Clin Oncol; 1986 Sep; 4(9):1374-9. PubMed ID: 3091778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
    van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
    Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
    Wu BZ
    Zhonghua Fu Chan Ke Za Zhi; 1987 Jan; 22(1):5-8, 61. PubMed ID: 3109851
    [No Abstract]   [Full Text] [Related]  

  • 56. A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
    Aabo K; Hald I; Hørbov S; Dombernowsky P; Hansen HH; Sørensen HM; Lundvall F; Nielsen NC; Sørensen BL
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):475-81. PubMed ID: 3891362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
    Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B
    Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intraperitoneal chemotherapy for advanced ovarian cancer.
    Lucas WE; Markman M; Howell SB
    Am J Obstet Gynecol; 1985 Jun; 152(4):474-8. PubMed ID: 3925784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
    Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
    J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.